Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer

BACKGROUND: To evaluate the efficacy and tolerability of the urokinase plasminogen activator (uPA) inhibitor upamostat in combination with gemcitabine in locally advanced pancreatic adenocarcinoma (LAPC). METHODS: Within a prospective multicenter study, LAPC patients were randomly assigned to receiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Heinemann, V, Ebert, M P, Laubender, R P, Bevan, P, Mala, C, Boeck, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590684/
https://www.ncbi.nlm.nih.gov/pubmed/23412098
http://dx.doi.org/10.1038/bjc.2013.62

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590684/
https://www.ncbi.nlm.nih.gov/pubmed/23412098
http://dx.doi.org/10.1038/bjc.2013.62

Ejemplares similares